Randomized Trial of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850)
Anna Fagotti(Università Cattolica del Sacro Cuore), Maria Gabriella Ferrandina(Università Cattolica del Sacro Cuore), Giuseppe Vizzielli(Università Cattolica del Sacro Cuore), Tina Pasciuto(Università Cattolica del Sacro Cuore), Francesco Fanfani(Università Cattolica del Sacro Cuore), Valerio Gallotta(Università Cattolica del Sacro Cuore), Pasquale Alessandro Margariti(Università Cattolica del Sacro Cuore), Vito Chiàntera(Università Cattolica del Sacro Cuore), Barbara Costantini(Università Cattolica del Sacro Cuore), Salvatore Gueli Alletti(Università Cattolica del Sacro Cuore), Francesco Cosentino(Università Cattolica del Sacro Cuore), Giovanni Scambia(Università Cattolica del Sacro Cuore)
Cited by 8
Abstract
(Abstracted from Int J Gynecol Cancer 2020;30:1657–1664) Diagnosis of ovarian, fallopian, and primary peritoneal cancer typically occurs in the setting of advanced disease. Two approaches to the initial treatment of these advanced malignancies are neoadjuvant chemotherapy followed by interval debulking surgery followed by adjuvant chemotherapy and primary debulking surgery followed by adjuvant chemotherapy.
Related Papers
No related papers found
Powered by citation graph analysis